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Summary
 
A reliable, nontoxic method of inducing transplantation tolerance is needed to overcome the
problems of chronic organ graft rejection and immunosuppression-related toxicity. Treatment
of mice with single injections of an anti-CD40 ligand antibody and CTLA4Ig, a low dose (3
Gy) of whole body irradiation, plus fully major histocompatibility complex–mismatched allo-
geneic bone marrow transplantation (BMT) reliably induced high levels (
 
.
 
40%) of stable (
 
.
 
8
mo) multilineage donor hematopoiesis. Chimeric mice permanently accepted donor skin grafts
(
 
.
 
100 d), and rapidly rejected third party grafts. Progressive deletion of donor-reactive host T
cells occurred among peripheral CD4
 
1
 
 lymphocytes, beginning as early as 1 wk after bone
marrow transplantation. Early deletion of peripheral donor-reactive host CD4 cells also oc-
curred in thymectomized, similarly treated marrow recipients, demonstrating a role for periph-
eral clonal deletion of donor-reactive T cells after allogeneic BMT in the presence of costimu-
latory blockade. Central intrathymic deletion of newly developing T cells ensued after donor
stem cell engraftment had occurred. Thus, we have shown that high levels of chimerism and
systemic T cell tolerance can be reliably achieved without myeloablation or T cell depletion of
the host. Chronic immunosuppression and rejection are avoided with this powerful, nontoxic
approach to inducing tolerance.
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T
 
he field of organ transplantation has enjoyed substan-
tial progress during the last two decades, resulting in
marked improvements in short-term graft survival. How-
ever, organ transplant recipients still face substantial risks of
long-term morbidity and mortality. Although modern im-
munosuppressive regimens have led to a dramatic reduc-
tion in the incidence of acute rejection episodes, they have
yet to achieve a similar effect for chronic rejection, which
is still the leading cause of graft loss during long-term fol-
low-up (1). In addition, the requirement for life-long im-
munosuppressive drug therapy carries a significant risk of
severe side effects, including tumors, infections, and meta-
bolic disorders. The reliable induction of donor-specific
tolerance would solve both problems by obviating the need
for chronic nonspecific immunosuppression and by abro-
gating detrimental immunological reactions against the al-
lograft.
Costimulation mediated by interactions of CD28 and
CD40 ligand (CD40L, CD154)
 
1
 
 on T cells, and B7 (CD80
and CD86; 2, 3) and CD40 (4–6), respectively, on APCs, is
of central importance for T cell–dependent immune re-
sponses. The use of antibodies that block these two path-
ways has recently led to improved graft survival in several
transplant models (7–10), with optimal results obtained
when both pathways are blocked simultaneously (11–13).
However, none of the reported treatment regimens were
shown to induce permanent primary skin graft acceptance
or deletional tolerance. Since deletional tolerance is the
most robust form of tolerance (14, 15), leading to the ab-
 
1
 
Abbreviations used in this paper:
 
 ATX, thymectomized; BM, bone marrow;
BMT, bone marrow transplantation; CD40L, CD40 ligand; FCM, flow
cytometric analysis; MR1, hamster anti–mouse CD40L mAb; MST, me-
dian survival time; WBI, whole body irradiation.
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sence of mature donor-reactive host cells, it may be the
most desirable form of tolerance for the clinical situation.
Hematopoietic cell transplantation has been known to be
associated with donor-specific tolerance for over 40 yr (16).
However, the routine use of hematopoietic cell transplan-
tation to induce tolerance in the clinical setting has been
prohibited thus far, largely because of the unacceptable
toxicity associated with the conditioning needed to achieve
engraftment of allogeneic bone marrow (BM) and because
of complications associated with allogeneic bone marrow
transplantation (BMT).
We now describe a method of inducing deletional T cell
tolerance that uses allogeneic BMT and costimulatory
blockade, leading to peripheral clonal deletion, high levels
of allogeneic stem cell engraftment, and permanent toler-
ance without requiring host T cell depletion or myeloabla-
tive conditioning.
 
Materials and Methods
 
Animals.
 
Female C57BL/6 (B6: H-2
 
b
 
), B10.A (B10.A: H-2
 
a
 
),
and A.SW (H-2
 
s
 
) mice were purchased from Frederick Cancer
Research Center (Frederick, MD) or from The Jackson Labora-
tory (Bar Harbor, ME). Mice were maintained in a specific patho-
gen–free microisolator environment, as previously described (17).
 
Conditioning and BMT.
 
Age-matched (6–8-wk-old) female
B6 mice received 3 Gy whole body irradiation (WBI) and were
injected intravenously on the same day (day 0) with unseparated
BM harvested from MHC-mismatched female B10.A donors
(10–12 wk old). A control group was injected intraperitoneally
with depleting doses of rat IgG2b anti–mouse CD4 mAb GK1.5
and anti–mouse CD8 mAb 2.43 on days 
 
2
 
5 and 
 
2
 
1, as previ-
ously described (18). Murine CTLA4Ig was injected intraperito-
neally as a single dose (0.5 mg) on day 
 
1
 
2, and hamster anti–
mouse CD40L mAb (MR1) was injected intraperitoneally on d0
(0.45 mg). CTLA4Ig was a gift from Bristol-Myers Squibb Phar-
maceuticals, Seattle, WA; the MR1 hybridoma was provided to
us by Dr. Randolph J. Noelle (Dartmouth Medical School, Leba-
non, NH). In the experiments indicated, thymectomies were per-
formed 4 wk before BMT, as described elsewhere (19, 20). The
completeness of thymectomy was confirmed at the time of death
2 wk after BMT by visual inspection and two-color FACS
 
Ò
 
 stain-
ing (Becton Dickinson, San Jose, CA) (CD4-FITC versus CD8-
PE) of mediastinal tissue. Mice showing any evidence of remain-
ing thymic tissue were excluded from analysis.
 
Flow Cytometric Analysis of Multilineage Chimerism.
 
Flow cy-
tometric analysis (FCM) of multilineage chimerism was per-
formed as previously described (21). In brief, forward angle and
90
 
8
 
 light scatter properties were used to distinguish lymphocytes,
monocytes, and granulocytes in peripheral white blood cells.
Two-color FCM was used to distinguish donor and host cells of
particular lineages, and the percentage of donor cells was calcu-
lated as previously described (21), by subtracting control staining
from quadrants containing donor and host cells expressing a par-
ticular lineage marker, and by dividing the net percentage of do-
nor cells by the total net percentage of donor plus host cells of
that lineage. Dead cells were excluded using propidium iodide
staining. Nonspecific Fc
 
g
 
R binding was blocked by anti–mouse
Fc
 
g
 
R mAb 2.4G2 (22). FITC-conjugated mAbs included anti-
CD4, anti-CD8, anti-B220 (all purchased from PharMingen, San
Diego, CA), and anti-MAC1 (Caltag Labs., San Francisco, CA).
Negative control mAb HOPC1-FITC, with no reactivity to
mouse cells, was prepared in our laboratory. Biotinylated anti–
H-2D
 
d
 
 mAb 34-2-12 and control mAb HOPC1 were developed
with PE-streptavidin.
 
FCM of T Cell Receptor V
 
b
 
 Families.
 
Peripheral blood lym-
phocytes were stained with FITC-conjugated anti-V
 
b
 
5.1/2,
V
 
b
 
11, and V
 
b
 
8.1/2 mAbs versus PE-conjugated anti-CD4 mAb
(all from PharMingen). Nonspecific PE-conjugated rat IgG2a
(PharMingen) served as negative control. Two-color FCM analy-
sis was performed on gated CD4
 
1
 
 cells. Splenocytes were stained
with FITC-conjugated anti-V
 
b
 
5.1/2, V
 
b
 
11, and V
 
b
 
8.1/2 mAbs
versus PE-conjugated anti-CD4 mAb (or anti-CD8 mAb;
PharMingen) and anti–34-2-12-biotin (BIO) developed with
CyChrome-streptavidin (PharMingen). Three-color FCM analy-
sis was performed on 34-2-12–negative, CD4
 
1
 
 (or CD8
 
1
 
) cells.
Thymocytes were stained with FITC-conjugated anti–TCR-
 
b
 
(PharMingen), anti–V
 
b
 
5.1/2, V
 
b
 
11, and V
 
b
 
8.1/2 versus BIO-
conjugated KH95 (anti-D
 
b
 
, PharMingen) developed with PE-strepta-
vidin. Two-color FCM analysis was performed on gated host-type
class I (KH95)–high cells, and the percentage of V
 
b
 
 positive cells
in this gate was corrected for the percentage of TCR-high cells in
the same gate, as previously described (23). For BIO.A controls,
gated 34-2-12-high cells were analyzed in a similar way. Back-
ground staining (as determined by nonreactive mAb HOPC-FITC)
was subtracted from the percentage of cells staining with each
anti-V
 
b
 
 mAb. 
 
P
 
 values were calculated using a two-tailed Stu-
dent’s 
 
t
 
 test.
 
Skin Grafting.
 
Full thickness tail skin from B10.A (donor-
specific) and fully MHC-mismatched A.SW (third party) mice
was grafted onto the lateral thoracic wall, secured with 5-0 silk
sutures and bandaids, and followed by visual and tactile inspec-
tions daily for 3 wk, and then at least one inspection every week
thereafter. Grafts were defined as rejected when 
 
,
 
10% of the
graft remained viable.
 
Results and Discussion
 
Stable Multilineage Hematopoietic Chimerism after Treatment
with CTLA4Ig Plus MR1.
 
To determine whether block-
ing the CD28 and CD40 costimulatory pathways could al-
low survival of fully MHC-mismatched BM and the induc-
tion of mixed chimerism and tolerance, B6 mice were
treated with 3 Gy WBI and received 1.5 
 
3
 
 10
 
7
 
 unseparated
BM cells from fully MHC-mismatched B10.A donors. A
single dose of MR1 and of CTLA4Ig was given either
alone or in combination, on days 0 and 
 
1
 
2, respectively.
Donor hematopoiesis was assessed at multiple time points
after BMT by FCM of peripheral white blood cells. By
staining with an mAb specific for donor class I versus vari-
ous lineage markers, the net percentage of donor cells
within these lineages was determined (see also Materials
and Methods).
The combined administration of CTLA4Ig plus MR1
led to high levels of chimerism in all hematopoietic lin-
eages, including T, B, and myeloid cells (Fig. 1 
 
D
 
). Donor
reconstitution averaged 
 
.
 
40% in all lineages by 7 wk, and
remained high during the observation period of 34 wk. Es-
pecially surprising was the high level of donor representa-
tion among CD4 and CD8 cells by 7 wk after BMT, even
though the hosts did not receive T cell depletion in their 
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conditioning. Donor T cell levels in the group treated with
MR1 plus CTLA4Ig were stable throughout long-term
follow-up (34 wk) and were, on average, higher than those
in a control group conditioned with anti-CD4– and anti-
CD8–depleting mAbs (Fig. 1 
 
A
 
) (21, 24). 15 out of 16
mice treated with the combination of MR1 and CTLA4Ig
developed high levels of chimerism (one mouse showed no
detectable chimerism and was excluded from further analy-
sis as an outlier). Treatment with MR1 alone led to high
levels of donor cells among myeloid lineages and B cells at
early time points after BMT, and to lower levels of chimer-
ism among CD4 and CD8 cells. However, the induction of
chimerism was less reliable in these mice than that in the
group receiving both costimulatory blocking reagents, and
donor chimerism was not stable in recipients of MR1 alone
(Fig. 1 
 
C
 
). Mice receiving CTLA4Ig alone did not show
chimerism in peripheral blood, as detected by FCM, at any
time after BMT (Fig. 1 
 
B
 
). Similarly, control animals re-
ceiving WBI and BM cells alone failed to show hematopoi-
etic chimerism (data not shown).
These results demonstrate that the simultaneous block-
ade of the CD28 and CD40 pathways allows the induction
of high levels of stable multilineage chimerism, and thus al-
logeneic pluripotent stem cell engraftment. In previous
protocols using immunocompetent hosts, this has only
been achieved with regimens that involve exhaustive de-
pletion of host T cells with mAbs or myeloablation by le-
thal irradiation or cytotoxic drugs (18, 21, 25–28). The
toxicity associated with myeloablation is generally consid-
ered to preclude its use in organ transplant recipients. The
completeness of T cell depletion necessary in experimental
protocols to achieve mixed chimerism (21, 26) would also
be of great concern in the clinical setting, given that the ca-
pacity of the adult human thymus to regenerate T cells
might be limited after such treatment (29).
 
Donor-specific Skin Graft Tolerance in Chimeras Prepared
with CTLA4Ig Plus MR1.
 
Primary skin grafting is consid-
ered the most stringent test of transplantation tolerance.
We therefore grafted donor (B10.A) and third party (A.SW)
full-thickness tail skin onto recipients at various time points
after BMT. Mice that received both CTLA4Ig and MR1,
plus 3 Gy WBI and BMT, permanently accepted donor
skin grafts placed 3, 6, or 10 wk after BMT (Fig. 2 
 
B
 
), with
the exception of two animals that rejected their grafts 57
and 76 d after graft placement, respectively. Third party
grafts were readily rejected (median survival time [MST] 
 
5
 
10 d), demonstrating the donor specificity of the tolerance
induced. This skin graft survival compares favorably even
to the control animals that were conditioned with T cell–
depleting antibodies, in which only 60% of donor skin
grafts survived more than 100 d (Fig. 2 
 
A
 
). Mice treated
with MR1 alone in addition to 3 Gy WBI and BMT dem-
onstrated prolongation of donor skin graft survival (MST 
 
5
 
42 d; Fig. 2 
 
A
 
). However, only two out of nine grafts were
accepted for 100 d. In contrast, mice receiving BMT after
3 Gy WBI and CTLA4Ig alone did not show prolonged
survival of donor skin grafts (MST 
 
5
 
 10 d), consistent with
the absence of chimerism.
These results demonstrate the presence of donor-specific
tolerance across a full MHC barrier in chimeras prepared
with MR1 plus CTLA4Ig. The ability of mixed chimeras
prepared with MR1 and CTLA4Ig to rapidly reject third
party skin grafts is evidence for their immunocompetence.
Although previous studies reported the ability of costimula-
tory blockade alone to prolong skin graft survival (8, 9, 11),
permanent skin graft acceptance and tolerance was not reli-
ably achieved (9, 30).
 
Deletion of Donor-reactive T Cells in Chimeras Prepared with
CTLA4Ig Plus MR1.
 
To examine whether deletion of
donor-reactive T cells occurs when chimerism is induced
with MR1 and CTLA4Ig, peripheral blood lymphocytes
were analyzed for the presence of certain V
 
b
 
 subunits on
their TCRs. The donor strain B10.A expresses I-E, which
is required to present superantigens derived from Mam-
mary tumor virus 8 and 9 endogenous retroviruses encoded
in the B6/B10 background genome. Developing thy-
Figure 1. High levels of multilineage do-
nor chimerism in peripheral blood for 34
wk after BMT. Results from one of two
similar experiments are shown as group av-
erages. All animals received 3 Gy WBI and
1.5 3 107 allogeneic BM cells on day 0.
Only MR1 plus CTLA4Ig together (D) al-
lowed the reliable induction of stable chi-
merism (n 5 5), with high levels of donor
cells in all lineages throughout the follow-
up. Administration of MR1 alone (C) led to
significant levels of chimerism, but chimer-
ism declined over time (n 5 5). When
CTLA4Ig was given alone (B), no chimer-
ism was detectable by FCM (n 5 4). A con-
trol group (n 5 5), receiving depleting doses
of anti-CD4 and anti-CD8 mAbs on day
25 and day 21 (A), showed substantial lev-
els of donor chimerism, with long-term lev-
els of T cell chimerism being significantly
lower than B cell, granulocyte, and mono-
cyte chimerism. 
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mocytes whose TCRs contain V
 
b
 
11 or V
 
b
 
5.1/2, which
bind to these superantigens, are deleted in I-E-positive
B10.A mice (31–33), but not in B6 mice, because they do
not express I-E (32, 34).
Partial deletion of V
 
b
 
5
 
1
 
 and V
 
b
 
11
 
1
 
 peripheral CD4 T
cells was observed as early as 1 wk after BMT in mice re-
ceiving 3 Gy WBI followed by MR1 plus CTLA4Ig (Fig.
3). The deletion became progressively more complete over
the ensuing weeks, and reached similar levels to those in
chimeras prepared with T cell depletion (data not shown)
(23). Deletion of these V
 
b
 
5
 
1
 
 and V
 
b
 
11
 
1
 
 cells was sus-
tained throughout the follow-up period (
 
.
 
6 mo in the first
experiment for which chimerism data are shown in Fig. 1).
Percentages of V
 
b
 
8-bearing CD4 cells, which do not rec-
ognize superantigens on the donor or host, were not re-
duced at any time point, ruling out a nonspecific deletional
process. Mice treated with BMT (plus 3 Gy WBI) and
MR1 alone showed early partial deletion of V
 
b
 
5 and
V
 
b
 
11, which was only transient in the experiment shown
(Fig. 3). However, in the experiment shown in Fig. 1, de-
letion was still observed at later time points for the group
receiving BMT (plus 3 Gy WBI) and MR1 alone, which
correlated with the higher initial levels of chimerism ob-
served for this group in this experiment. Control animals
receiving 3 Gy WBI plus BMT alone or BMT (plus 3 Gy
WBI) with CTLA4Ig failed to show any V
 
b
 
5 or V
 
b
 
11 de-
letion. As expected, deletion of V
 
b
 
5 and V
 
b
 
11 did not oc-
cur in control animals receiving WBI and MR1 plus
CTLA4Ig without BMT (data not shown). Downregula-
Figure 2. Permanent survival of donor-specific skin grafts in chimeras
prepared with 3 Gy WBI and allogeneic (B10.A) BM cells and treatment
with MR1 plus CTLA4Ig. Combined results from two experiments are
shown. Recipients were grafted with donor-specific (B10.A) and third
party (A.SW) skin grafts at 3, 6, or 10 wk after BMT. Mice receiving the
full treatment of BMT and MR1 plus CTLA4Ig accepted donor skin
grafts (B) permanently (12 out of 14), with the exception of 2 animals that
rejected their grafts at days 57 and 76, respectively. 9 grafts have been ac-
cepted in perfect condition for .110 d, and 5 grafts for .140 d. Third-
party skin grafts (B) were rejected in the expected time frame (MST 5
10 d). MR1 alone (A) led to prolongation of donor-specific skin graft sur-
vival (MST 5 42 d), but only 2 out of 9 grafts survived .100 d.
CTLA4Ig alone (A) failed to improve skin graft survival (n 5 7, MST 5
10 d). Control mice treated with 3 Gy WBI plus BMC (n 5 4) and mice
receiving 3 Gy WBI and MR1 plus CTLA4Ig alone (without BMT, data
not shown) rejected donor skin within 2 wk. In a control group prepared
with T cell–depleting mAbs on day 25 and day 21 plus BMT (plus 3 Gy
WBI) (n 5 5), donor skin grafts were permanently accepted in 60% of
mice. Third party grafts were rejected within 2 wk in all groups.
Figure 3. Specific deletion of donor-reactive peripheral T cells in re-
cipients of BMT and MR1 plus CTLA4Ig. Results from one of two sim-
ilar experiments are shown. FCM was performed at indicated time points,
with the percentage of Vb-positive cells being determined among gated
CD41 PBLs. The mean percentage of CD41 lymphocytes expressing
Vb5.1/2 or Vb11 was significantly lower in mice receiving BM cells
(BMC) (plus 3 Gy WBI) with MR1 plus CTLA4Ig (n 5 10) than in re-
cipients of BMC (plus 3 Gy WBI) alone (n 5 4), as early as 1 wk after
BMT (P ,0.01 for Vb11, P ,0.05 for Vb5). The specific deletion grad-
ually became more complete at 3, 5, and 8 wk after BMT and was sus-
tained for the length of follow-up. The percentage of Vb8.1/21 CD4
cells remained similar in all groups, demonstrating specificity of the
Vb5.1/2 or Vb11 deletion in mixed chimeras. Mice receiving BMC (plus
3 Gy WBI) alone or in addition to CTLA4Ig (n 5 4) did not show any
deletion, nor did control mice treated with MR1 plus CTLA4Ig alone
(without BMC; data not shown). MR1 alone led only to a slight and
transient deletion in this experiment (n 5 5). Error bars indicate standard
deviation. P values are shown for comparison with the control group re-
ceiving 3 Gy WBI plus BMC. NL B6 denotes naive C57BL/6 control;
NL B10.A denotes naive B10.A control.2041 Wekerle et al.
tion of the level of TCR expression instead of deletion
seems an unlikely explanation for the reduction in Vb51
and Vb111 CD4 T cells in chimeras, since the intensity of
the Vb5 and Vb11 staining on the cells remaining in the
blood at 1 and 3 wk after BMT was similar to that in non-
transplanted controls (data not shown). Thus, no evidence
for TCR downmodulation was observed.
These results indicate that in BMT recipients treated
with MR1 plus CTLA4Ig and 3 Gy WBI, donor-reactive
host T cells start to disappear from the periphery very soon
after BMT. Neither CTLA4Ig nor MR1 (35, 36) is known
to be directly cytotoxic to the T cells to which they bind. 3
Gy WBI causes only transient and mild leukopenia (37)
and only partial T cell depletion (Sykes, M., unpublished
data). This time course suggests that the deletion observed
at 1 wk is not entirely due to intrathymic mechanisms, since
a sufficient number of thymocytes would be unlikely to emi-
grate from the thymus during this period to “dilute” the
preexisting peripheral repertoire to an extent that could ex-
plain the observed decrease in Vb51 and Vb111 CD4 lym-
phocytes in PBLs.
Extrathymic Clonal Deletion Occurs in the Early Period after
BMT and Costimulatory Blockade. To directly determine
whether peripheral deletion is responsible for the early de-
cline in donor-reactive CD4 T cells in chimeras, thymec-
tomized (ATX) B6 mice received B10.A BM cells after
conditioning with 3 Gy WBI and MR1 plus CTLA4Ig. As
shown in Fig. 4 A, ATX mice demonstrated partial dele-
tion of Vb51 and Vb111 peripheral blood CD4 cells 1 wk
after BMT, and the degree of deletion was comparable to
that in euthymic recipients. Vb81 CD4 cells were not di-
minished, indicating the specificity of the deletion for su-
perantigens presented by the donor. Similarly treated ATX
mice not receiving BMT showed no reduction in the per-
centage of Vb51 or Vb111 CD4 cells compared to un-
treated B6 mice (Fig. 4 A), demonstrating that this periph-
eral deletion occurred specifically in response to donor
marrow in BMT recipients.
Further evidence that peripheral deletion plays a role in
the early period after BMT in this model was obtained
from chimeras killed 20 wk after BMT and CTLA4Ig plus
MR1. Among splenocytes of these mice, the percentage of
Vb51 and Vb111 cells among CD41 T cells was reduced
to similar levels as in normal, control B10.A mice. How-
ever, the percentages of Vb51 and Vb111 cells were sub-
stantially higher among CD81 splenocytes than among
CD41 splenocytes. Nevertheless, the percentages of CD8
splenocytes using these Vb were significantly lower than
among those of normal, control B6 mice (Fig. 4 B). As dis-
cussed below, this difference most likely reflects the dilu-
tion of the peripheral CD8 pool by new thymic emigrants
that are tolerized by a central deletion mechanism in the
chimeras.
Peripheral deletion has been shown to be one conse-
quence of powerful T cell responses in vivo, but it has only
been reported after marked expansion of antigen-recogniz-
ing cells (38, 39). Although 1 wk after BMT was the earli-
Figure 4. Extrathymic clonal deletion after BMT and costimulatory
blockade with CTLA4Ig and MR1. (A) ATX recipients (n 5 6) showed
specific, partial deletion of Vb5.1/21 and Vb111 CD4 cells in PBLs, 1
wk after BMT plus CTLA4Ig and MR1 and 3 Gy WBI. A similar degree
of deletion was observed in euthymic controls (n 5 5) prepared with the
same conditioning. CD4 cells in ATX controls receiving CTLA4Ig plus
MR1 and WBI without BMT (n 5 4) did not show deletion of these Vb.
The percentage of Vb1 cells was determined by FCM analysis of gated
CD41 PBLs. P values are shown for comparison between ATX BMT re-
cipients receiving CTLA4Ig plus MR1 and ATX non-BMT controls. (B)
In two euthymic chimeras killed 20 wk after BMT (under cover of 3 Gy
WBI, plus treatment with CTLA4Ig plus MR1), Vb5.1/21 and
Vb111CD41 splenocytes (SPL) were deleted to the same extent as in na-
ive B10.A controls (top). In contrast, the percentage of Vb5.1/21 and
Vb111CD81 splenocytes was reduced compared to naive B6 mice, but
was substantially higher than in naive B10.A mice (middle). Mature
Vb5.1/21 and Vb111 thymocytes (THY) showed deletion comparable to
B10.A at the same time (bottom). A control mouse receiving WBI and
CTLA4Ig plus MR1 (but no BMT) showed no deletion in either spleno-
cytes or thymocytes. The percentage of Vb1 cells was determined by
FCM analysis in gated CD41 (or CD81) 34-2-12–negative splenocytes,
and in gated KH-95high (i.e., Db high)-thymocytes (or Dd high in the case of
BIO.A controls; see Materials and Methods). NL B6 denotes naive
C57BL/6 control; NL B10.A denotes naive B10.A control.2042 Induction of Mixed Chimerism and Tolerance with Anti-CD40L and CTLA4Ig
est time point at which donor-reactive host T cells were
examined, we did not see evidence of such initial expan-
sion. More recently, in vitro evidence has demonstrated
that costimulatory signals play a prominent role in prevent-
ing apoptotic cell death after TCR engagement (40–42).
However, apoptosis induced in vivo by antigen encoun-
tered in the presence of costimulatory blockade has not
been described previously.
Evidence for Central Deletion of Donor-reactive T Cells in
Long-Term Chimeras. Mature recipient T cells (including
both CD4 and CD8 cells) in the thymus showed marked
deletion of Vb5 and Vb11 when animals were killed 20 wk
after BMT (Fig. 4 B), demonstrating that newly developing
donor-reactive thymocytes are effectively deleted during
maturation in the thymus in long-term chimeras.
Together, our data suggest a model whereby extrathy-
mic clonal deletion occurs early after BMT under cover of
costimulatory blockade. Allogeneic pluripotent stem cell
engraftment is thus permitted, and subsequent tolerization
of newly-developing donor-reactive thymocytes occurs by
deletional mechanisms in the thymus similar to that which
occurs in animals initially treated with T cell–depleting
mAbs (23). This model also explains the discrepancy in the
extent of deletion of CD4 cells compared to CD8 cells in
the peripheral tissues of long-term chimeras. Vb51 and
Vb111 CD4 cells are subject to deletion both intrathymi-
cally and in the periphery when they recognize superanti-
gen plus donor MHC class II. CD8 cells expressing these
Vb are efficiently deleted intrathymically (43) at the
CD81CD41 stage of maturation. However, CD81CD42
cells are not very effectively deleted extrathymically (38,
39, 44), although weak proliferative activity to superanti-
gens presented by class II MHC in the periphery has been
described (39, 44). It follows that the substantial difference
in the degree of deletion between peripheral CD4 and
CD8 cells is most likely due to the more extensive contri-
bution of extrathymic deletion among the CD4 compared
to the CD8 cells preexisting at the time of BMT. This con-
clusion is further supported by the observation that ATX
recipients of BMT plus costimulatory blockade demon-
strated a significant reduction of Vb51 and Vb111 CD4
splenocytes, but not of CD8 splenocytes, at 2 wk after
BMT (data not shown).
Previously published reports showed that costimulatory
blockade as the sole immunosuppressive treatment can al-
low the permanent acceptance of vascularized allografts
grafted at the same time (8, 11, 12). However, the organ
allografts themselves probably play a critical role in toler-
ance induction in these models, and deletional tolerance
has not been demonstrated. In contrast, solid organ (skin)
grafting was not required in the induction phase of toler-
ance in our model. Instead, the permanent engraftment of
donor hematopoietic cells ensured the tolerization of pre-
existing host T cells and of T cells that developed subse-
quent to the disappearance of the costimulatory blocking
agents from the circulation. This later tolerance occurred
through intrathymic deletional mechanisms (Fig. 4), pre-
sumably as a consequence of the presence of donor-derived
APCs in the thymus, as has been demonstrated in long-
term mixed chimeras prepared with other regimes that in-
volve initial depletion of the T cell repertoire with mAbs
(23). In previous studies, administration of donor lympho-
cytes in the presence of anti-CD40L has been shown to al-
low survival of pancreatic islet allografts (45) and to pro-
long survival of MHC-mismatched skin allografts (9).
However, chimerism and deletion were not evident in
those studies. Thus, our studies provide the first demonstra-
tion that costimulatory blockade leads to peripheral dele-
tion of donor-reactive T cells, then allows the engraftment
of fully MHC-mismatched, allogeneic pluripotent stem
cells, which induce central tolerance among T cells that
subsequently develop in the thymus.
BMT with CTLA4Ig plus MR1 specifically eliminates
donor-reactive T cells, while avoiding the nonspecific de-
pletion or suppression of T cells, which is a component of
all clinically available immunosuppressive strategies, and
can lead to severe complications. This new treatment pro-
tocol would be suitable for both cadaveric and living-related
organ transplantation, as it allows the reliable induction of
deletional tolerance with a nontoxic conditioning regimen
beginning on the day of transplantation. Since the periph-
eral T cell repertoire is not globally depleted by the condi-
tioning and only a low, minimally myelosuppressive dose
of WBI is given, the clinical potential of this approach is
extraordinarily high.
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